Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Supernus Pharmaceuticals Inc
LSE:0LB2
Supernus Pharmaceuticals Inc
LSE:0LB2
Price:
44
USD
-2.5%
Market Closed
Market Cap:
$2.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
Sappi Ltd
F:SPI
|
ZA |
|
Black Iron Inc
TSX:BKI
|
CA |
|
S
|
Sanjivani Paranteral Ltd
BSE:531569
|
IN |
|
S
|
State Street Corp
XMUN:ZYA
|
US |
|
C
|
Christian Dior SE
OTC:CHDRY
|
FR |
|
R
|
Restaurant Brands International Inc
F:0R6
|
US |
|
E
|
Enbridge Inc
LSE:0KTI
|
CA |
|
Cenntro Inc (The Corporation)
NASDAQ:CENN
|
US |
|
M
|
Melia Hotels International SA
SWB:MEL
|
ES |
|
C
|
Colgate-Palmolive Co
XMUN:CPA
|
US |
|
E
|
Exelon Corp
SWB:PEO
|
US |
|
Yondoshi Holdings Inc
TSE:8008
|
JP |
|
C
|
CBRE Group Inc
SWB:RF6
|
US |
Wall St Price Targets
0LB2 Price Forecast
Based on 6 analysts
Based on 6 analysts
+50% Upside
from
$44
today
Supernus Pharmaceuticals Inc (0LB2)’s 12-month stock price forecast through September 2027 has a consensus target of $66, implying 50% upside. The forecast is based on price targets from 6 Wall Street analysts.
0LB2 Analyst Rating
No ratings yet
No ratings yet
Supernus Pharmaceuticals Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0LB2's stock price target?
Price Target
66
USD
66
USD
According to Wall Street analysts, the average 1-year price target for 0LB2 is 66 USD with a low forecast of 55.3 USD and a high forecast of 70.03 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.